What CyberomiX does

CyberomiX Co., Ltd. (株式会社CyberomiX) is a Japanese contract research organization founded in 2023 and headquartered in Kyoto. The company provides single-cell and spatial transcriptomics analysis services — including single-cell (nuclear) RNA/ATAC-seq, Visium HD spatial transcriptomics, spatial transcriptomics with single-nucleotide mutation detection, RNA-seq, and bioinformatics — to pharmaceutical companies, biotech firms, and academic researchers, with full consultation support from study design through data interpretation. Its core technical differentiator is the C-DIAM browser-based analysis platform launched in March 2026, which allows researchers to complete single-cell and spatial transcriptomics analyses without command-line operations or software installation, supplemented by a custom bioinformatics workflow for signal pathway identification and intercellular communication analysis.

The company's revenue model is a hybrid of fee-for-service project work (one-time engagement) and emerging recurring software licensing via C-DIAM. Pricing is project-based and negotiated, with the company explicitly positioning on "highest quality at the lowest domestic prices in Japan." Go-to-market is sales-led and event-driven: CyberomiX actively participates in major Japanese scientific societies (Japanese Pathology Society, Japanese Biochemistry Society, Japanese Cancer Association) through booth exhibits, oral presentations, and sponsored seminars, while also building local brand awareness through radio programs and Kyoto community engagement.

CyberomiX differentiates through a proprietary clinical network enabling access to diverse clinical specimens across multiple organs and tumor types, an accumulated protocol library from 10+ years of prior research, and an integrated "seed-to-harvest" workflow combining laboratory experimentation with downstream data analysis. The team is composed of pathology, genomics, and data science experts positioning themselves as a platform that generates patents and IP rather than licensing existing university patents. Notable partnerships include Twist Bioscience ProLab certification (May 2025) and an international internship collaboration with CRCC Asia (March 2025). Geographic operations are currently limited to Japan.

Name

CyberomiX

Legal name

株式会社CyberomiX

Website

https://cyberomix.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

CyberomiX is a Kyoto-based Japanese contract research organization founded in 2023 that provides single-cell and spatial transcriptomics analysis services to pharmaceutical, biotech, and academic researchers, complemented by its C-DIAM browser-based analysis platform launched in 2026.

Ownership category

akta.pro rank

Product category

Genomics Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Single-cell analysis
• Spatial transcriptomics
• Genomics research services
• Bioinformatics analysis
• RNA sequencing

Headquarters

HQ city

Kyoto-shi

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Research Services: Fee-for-service model providing genomics and bioinformatics analysis services to pharmaceutical companies, biotech firms, and academic researchers. Services include single-cell RNA/ATAC-seq analysis, Visium spatial transcriptomics, RNA-seq, and bioinformatics. Services are provided on a project basis with full consultation support from research design through data interpretation.
2. C-DIAM Platform Licensing: License sales for the web-based C-DIAM analysis platform that enables command-free, installation-free genomic analysis in web browsers.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

CyberomiX provides contract genomics and single-cell/spatial transcriptomics analysis services to pharmaceutical companies, biotech firms, and academic researchers, covering single-cell RNA/ATAC-seq, Visium HD spatial transcriptomics, spatial transcriptomics with single-nucleotide mutation detection, RNA-seq, and bioinformatics analysis. The company complements these services with C-DIAM, its proprietary web browser-based analysis platform that enables genomic data analysis without command-line usage or software installation.

Product overview

CyberomiX operates as a genomics and single-cell analysis service provider offering a portfolio of laboratory analysis services and a web-based analysis platform. The core service offerings include single-cell RNA/ATAC-seq analysis, Visium spatial transcriptomics analysis, spatial transcriptomics with single-nucleotide genome mutation detection, RNA-seq analysis, and bioinformatics analysis—each led by expert consultants providing full support from experimental design through data interpretation. C-DIAM serves as the company's browser-based analysis platform enabling analysis completion without command-line operations or software installation. The company leverages specialized laboratory equipment including CytAssist, Chromium X, gentleMACS, and advanced microscopy systems, and targets disease areas including liver cancer, gynecological cancers, blood cancers, head and neck cancers, kidney disease, and COVID-19.

Differentiator

Problem solved

Functional benefit

Products and services

• C-DIAM Analysis Platform Web browser-based analysis platform that enables complete single-cell and spatial transcriptomics data analysis without requiring command-line usage or software installation. Sold via license to researchers and organizations seeking to perform genomic analysis directly in a web browser.
• Single-cell (nuclear) RNA/ATAC-seq Analysis Service Contract research service that examines individual cell gene expression and chromatin accessibility at single-cell resolution, precisely capturing cell-specific functions and states. Targeted at pharmaceutical companies, biotech firms, and academic researchers.
• Visium HD Spatial Transcriptomics Analysis Service Contract research service using Visium HD technology that enables simultaneous analysis of gene expression and positional information for fine regions within tissue, providing detailed understanding of cell states and functions in specific tissue areas. Targeted at researchers requiring spatial gene expression profiling.
• Spatial Transcriptomics with Single-Nucleotide Mutation Detection Service Advanced spatial transcriptomics contract research service capable of detecting genome mutations at single-nucleotide resolution, combining spatial tissue information with high-precision mutation analysis. Targeted at researchers requiring spatially resolved mutation profiling.
• RNA-seq Analysis Service Customizable contract RNA-seq analysis service for diverse data types that leverages statistics and programming to deliver deep understanding and new insights from gene expression data. Targeted at researchers requiring bulk gene expression profiling.
• Bioinformatics Analysis Service Comprehensive gene expression profiling contract research service using next-generation sequencing technology, providing exhaustive measurement of gene expression levels across the entire genome. Targeted at researchers requiring whole-genome expression analysis.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Twist Bioscience ProLabcoreTechnology or Integration · 7 May 2025CyberomiX received certification as a Twist Bioscience ProLab partner, enabling them to provide validated genomics services using Twist Bioscience products and technologies. This partnership enhances their service capabilities and credibility in the genomics research market.
• CRCC AsiaminorOthersCollaboration on an overseas university student internship project, bringing international perspectives and talent to CyberomiX operations.
• FM87.0 RADIO MIX KYOTOminorGTM or Marketing PartnerCyberomiX sponsors and appears on the radio program 'CyberomiXの京都あれこれ解析中！', using local radio to build brand awareness and community engagement in the Kyoto region.

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Takara Bio Inc. Japanese biotechnology company providing reagents, instruments (including single-cell and NGS), and contract research services for genomics and cell biology. Overlaps with CyberomiX in single-cell analysis services and bioinformatics for Japanese pharma/biotech customers.
• Riken Genesis Co., Ltd. Japanese clinical genomics services provider offering NGS-based testing and research support to pharmaceutical and medical institutions. Comparable as a Japan-headquartered genomics CRO serving pharma, biotech, and clinical researchers.
• DNA Chip Research Inc. Japanese genomics analysis services company providing microarray, NGS, and bioinformatics to pharma, biotech, and academic researchers. Directly comparable as a Japan-based contract research services provider in genomics with overlapping customer base.

Broad incumbents

• Illumina, Inc. Global leader in NGS sequencing platforms and increasingly in single-cell/spatial (via partnerships and acquisitions such as Fluent Biosciences). Comparable as a broad incumbent in genomics enabling technologies underlying CyberomiX's services.
• 10x Genomics: US-based provider of single-cell and spatial biology platforms (Chromium, Visium HD, Xenium). Both a key upstream supplier to CyberomiX and a broad incumbent offering competing analysis tools and services globally across the single-cell transcriptomics value chain.
• Bruker (NanoString Spatial Biology): Acquired NanoString's spatial transcriptomics portfolio (GeoMx, CosMx, CellProfiler). Comparable as an incumbent in spatial transcriptomics, overlapping with CyberomiX's Visium HD-based services and broader pharma/biotech research market.

Emerging players

• Parse Biosciences: US-based company offering scalable single-cell sequencing technology (Evercode) with no instrument requirements. Partial overlap with CyberomiX's single-cell services as both target researchers needing scalable single-cell analysis, though Parse is a platform vendor rather than service provider.

Regional players

• Novogene Corporation: Chinese-founded genomics services provider offering NGS, single-cell, and bioinformatics globally. Comparable in providing contract sequencing and bioinformatics services to pharma and academia, though based in a different region with limited Japan presence.
• BGI Genomics Co., Ltd. Chinese genomics services company providing NGS, single-cell, and bioinformatics globally. Comparable as a large-scale genomics CRO serving pharma, biotech, and clinical customers, though based in China with limited direct Japan overlap.
• Macrogen Inc. Korean-headquartered genomics services company offering NGS, single-cell, and bioinformatics globally with operations in Japan. Comparable as an Asian genomics CRO serving pharma and academic customers, though operating from a different geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CyberomiX
• YouTubeyoutube.com/@CyberomiX
• Instagraminstagram.com/cyberomix_inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CyberomiX